{"id":"https://openalex.org/W3045137922","doi":"https://doi.org/10.1002/cpdd.853","title":"Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin\u2010Dependent Kinase 4/6 Inhibitor, in Healthy Subjects","display_name":"Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin\u2010Dependent Kinase 4/6 Inhibitor, in Healthy Subjects","publication_year":2020,"publication_date":"2020-07-24","ids":{"openalex":"https://openalex.org/W3045137922","doi":"https://doi.org/10.1002/cpdd.853","mag":"3045137922","pmid":"https://pubmed.ncbi.nlm.nih.gov/32706937"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.853","doi":"https://doi.org/10.1002/cpdd.853","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.853","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020583341","display_name":"Yan Ji","orcid":"https://orcid.org/0000-0001-9569-0574","observed_orcids":["https://orcid.org/0000-0001-9569-0574"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yan Ji","raw_affiliation_strings":["Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102018126","display_name":"Ahmed M. Abdelhady","orcid":"https://orcid.org/0000-0001-9404-5397","observed_orcids":["https://orcid.org/0000-0001-9404-5397"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmed M. Abdelhady","raw_affiliation_strings":["Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041463490","display_name":"Tanay S. Samant","orcid":"https://orcid.org/0000-0003-3474-4406","observed_orcids":["https://orcid.org/0000-0003-3474-4406"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanay S. Samant","raw_affiliation_strings":["Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102930061","display_name":"Shu Yang","orcid":"https://orcid.org/0000-0002-9777-5923","observed_orcids":["https://orcid.org/0000-0002-9777-5923"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shu Yang","raw_affiliation_strings":["Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006919907","display_name":"Karen Rodriguez Lorenc","orcid":"https://orcid.org/0009-0007-1286-7778","observed_orcids":["https://orcid.org/0009-0007-1286-7778"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Rodriguez Lorenc","raw_affiliation_strings":["Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Co., East Hanover, New Jersey, USA","institution_ids":["https://openalex.org/I4210117619"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5020583341"],"corresponding_institution_ids":["https://openalex.org/I4210117619"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":null,"fwci":0.8897,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.73228777,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"9","issue":"7","first_page":"855","last_page":"866"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":1.0},{"id":"https://openalex.org/keywords/cyclin-dependent-kinase-4-6-inhibitors","display_name":"cyclin-dependent kinase 4/6 inhibitors","score":0.9210000038146973},{"id":"https://openalex.org/keywords/absolute-oral-bioavailability","display_name":"absolute oral bioavailability","score":0.9279999732971191},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.9900000095367432},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.847000002861023},{"id":"https://openalex.org/keywords/systemic-clearance","display_name":"systemic clearance","score":0.6710000038146973},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.9729999899864197},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.7630000114440918},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5170000195503235}],"concepts":[{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.9090708494186401},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.795047402381897},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7206459641456604},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7038292288780212},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5375987887382507},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5148336291313171},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.509463369846344},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.49103593826293945},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.46254441142082214},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4201311469078064},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004339","descriptor_name":"Drug Compounding","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012449","descriptor_name":"Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051358","descriptor_name":"Cyclin-Dependent Kinase 4","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051361","descriptor_name":"Cyclin-Dependent Kinase 6","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.853","doi":"https://doi.org/10.1002/cpdd.853","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.853","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:32706937","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32706937","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:oak.novartis.com:41332","doi":null,"is_oa":false,"landing_page_url":"https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.853","pdf_url":null,"source":{"id":"https://openalex.org/S4306400709","display_name":"The Novartis Repository (Novartis)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1283582996","host_organization_name":"Novartis (Switzerland)","host_organization_lineage":["https://openalex.org/I1283582996"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310388","display_name":"Novartis Pharmaceuticals Corporation","ror":"https://ror.org/028fhxy95"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W2041468663","https://openalex.org/W2137177885","https://openalex.org/W2137620209","https://openalex.org/W2145363003","https://openalex.org/W2402797587","https://openalex.org/W2513801928","https://openalex.org/W2560635244","https://openalex.org/W2735705321","https://openalex.org/W2765248184","https://openalex.org/W2769143729","https://openalex.org/W2773706638","https://openalex.org/W2799449726","https://openalex.org/W2802776309","https://openalex.org/W2804105316","https://openalex.org/W2805575723","https://openalex.org/W2896664662","https://openalex.org/W2948069739","https://openalex.org/W2963172953","https://openalex.org/W3033840722","https://openalex.org/W3133509869","https://openalex.org/W4205331907","https://openalex.org/W4239051461"],"related_works":["https://openalex.org/W3215103675","https://openalex.org/W4391052188","https://openalex.org/W7126036178","https://openalex.org/W4413296370","https://openalex.org/W1985398792","https://openalex.org/W2769143729","https://openalex.org/W3033840722","https://openalex.org/W2513801928","https://openalex.org/W2126866083","https://openalex.org/W2360949008"],"abstract_inverted_index":{"Ribociclib,":[0],"a":[1,42,47,57,72,80],"selective":[2],"and":[3,12,68,79,93,138,160,169,183,195,201],"potent":[4],"cyclin-dependent":[5],"kinase":[6],"4/6":[7],"inhibitor,":[8],"has":[9],"demonstrated":[10,173],"safety":[11],"efficacy":[13],"in":[14,19,35,100,232],"combination":[15],"with":[16,56,134,223],"endocrine":[17],"therapy":[18],"hormone":[20],"receptor-positive,":[21],"human":[22],"epidermal":[23],"growth":[24],"factor":[25],"receptor-2-negative":[26],"advanced":[27],"breast":[28],"cancer.":[29],"In":[30],"2":[31],"open-label":[32],"crossover":[33],"studies":[34],"healthy":[36],"participants,":[37],"the":[38,69,107,139,157,167,186,205],"absolute":[39],"bioavailability":[40,105],"of":[41,46,62,71,91,106,123,143,166,180,209],"single":[43,58],"oral":[44,104,158],"dose":[45],"ribociclib":[48,60,73,81,92,109,124],"600-mg":[49,74,82,108],"tablet":[50,75,110,168],"(n":[51,65,76,84],"=":[52,66,77,85],"16)":[53],"was":[54,87,111,125,145,172,220],"compared":[55,133],"intravenous":[59,163],"infusion":[61],"150":[63],"mg":[64],"16),":[67],"bioequivalence":[70,207],"31)":[78,86],"capsule":[83,170],"evaluated.":[88],"The":[89,103,118,176,213],"pharmacokinetics":[90],"its":[94],"major":[95],"metabolite,":[96],"LEQ803,":[97],"were":[98,154,198,230],"assessed":[99],"both":[101,224],"studies.":[102],"65.8%":[112],"(90%":[113],"confidence":[114],"interval":[115],"[CI],":[116],"59.1-73.2%).":[117],"geometric":[119,140,177],"mean":[120,141,178],"systemic":[121],"clearance":[122],"moderate":[126],"(40.2":[127],"L/h;":[128],"27.4%":[129],"intersubject":[130],"variability":[131],"[CV%])":[132],"hepatic":[135],"blood":[136],"flow,":[137],"volume":[142],"distribution":[144],"high":[146],"(979":[147],"L;":[148],"25.2":[149],"CV%).":[150],"LEQ803-to-ribociclib":[151],"metabolic":[152],"ratios":[153,179],"0.198":[155],"for":[156,162,174],"administration":[159],"0.125":[161],"infusion.":[164],"Bioequivalence":[165],"formulations":[171],"ribociclib.":[175],"maximum":[181,218],"concentration":[182,194,219],"area":[184],"under":[185],"curve":[187],"from":[188],"time":[189,215],"0":[190],"to":[191,196,211,216],"last":[192],"quantifiable":[193],"infinity":[197],"1.01,":[199],"1.00,":[200],"0.937,":[202],"respectively,":[203],"within":[204],"predefined":[206],"range":[208],"0.80":[210],"1.25.":[212],"median":[214],"reach":[217],"3":[221],"hours":[222],"formulations.":[225],"No":[226],"serious":[227],"adverse":[228],"events":[229],"observed":[231],"either":[233],"study.":[234]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-07-29T00:00:00"}